PATIENTS. A Pure player of AI for Drug (re)positioning & Treatments Optimization at your service  

All over the world, patients need treatments - 7 000 orphan diseases -, better treatments and more secure treatments


They deserve a more fertile R&D while at best only 1 out of 14 drug-candidates entering the clinical phase will get an FDA approval (Dowden & Munro - 2019) and while its overall annual $165B budget leads to only 40-50 FDA approvals.

Therefore, INSILIANCE focuses its mission, its strategy and its resources on AI for Drug (Re)positioning & Treatments Optimization, with AI considered as a high potential lever for innovation.

EFFICACITY. AI can reduce risks and costs, attract serendipity and improve decision making


Drug discovery is a data-driven environment with a massive of data such as medical images, genomic profiles, metabolites, molecular structures and biological information.


AI can use machine learning and deep learning to correlate, assimilate, and connect these big data more rapidly in order to help discover patterns in the data pools.


By reviewing scientific literature, AI can make connections that provide possible hypotheses for drug (re)positioning.

Therefore, INSILIANCE focused its AI expertise on complementary and synergistic R&D projects in order to get key knowledge from "Omics", Scientific Literature, Pharmaceutical Patents and Real-World Data Bases, with respect to rules, regulations and patients privacy.

CROSS-CULTURAL. Validating health data, algorithms design and results requires BioData Science + Health researchers and executive's collaboration   


Because medicine is an art, experience, expertise, intuition, sense of others, transparency, confidentiality and ethics are crucial for the effectiveness and the efficiency of AI for Drug (Re)positioning & Treatments Optimization projects. 


And each partner in an AI project wishes to avoid any "black box" effect throughout the process, from the selection of data sets to the exploitation of results, including the algorithm fine-tuning.

Therefore, INSILIANCE always associates MDs, pharmacists and biologists with computer and BioData scientists and, whenever needed, business developers, economists, regulators, ethical referents and executives, in projects.

PARTNERSHIPS. Together, we can share the mind of Champollion applied to Health Data in order to achieve our missions for patients

If patients want drugs with a high therapeutic value, MDs want a better knowledge of possible response to treatments in order to optimizing prescriptions and care pathways. And public health authorities and health insurers want to improve resources allocation.

Like hieroglyphs, scientific literature, pharmaceutical patents, "omics", real-world data (EHR, connected objects, apps and Web) can better deliver their full potential of meaning and semantic health key knowledge.

Therefore, INSILIANCE is developing its CHAMPOLLION AI PLATFORM to help every partner committed to drug discovery and treatments optimization.

© 2020 Insiliance - Health & AI Scientific Consortiums and Projects  for Drug (Re)positioning and Treatments Optimization - Paris - France